Stockreport

UroGen Pharma's JELMYTO And UGN-102: A Strong Buy In The Urological Cancer Sector [Seeking Alpha]

UroGen Pharma Ltd. - Ordinary Shares  (URGN) 
Last urogen pharma ltd. - ordinary shares earnings: 3/2 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.urogen.com
PDF Summary UroGen Pharma stock is a strong buy due to its innovative RTGel technology and promising pipeline, including JELMYTO and UGN-102, targeting urological cancers [Read more]